{"preliminary_commentary":{"by_channel":{"x_thread":3,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["enfortumab vedotin"],["enfortumab vedotin","pembrolizumab"]],"indication":"rare genitourinary tumors","name":"E-VIRTUE","nct_id":"NCT06041503","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=e-virtue-nct06041503. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Treatment with enfortumab vedotin","label":"Arm 1","type":"EXPERIMENTAL"},{"description":"Treatment with enfortumab vedotin and pembrolizumab","label":"Arm 2","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-10-01","type":"ESTIMATED"},"conditions":["Adenocarcinoma of the Bladder","Squamous Cell Carcinoma of the Bladder","Testicular Germ Cell Tumors"],"enrollment":{"count":68,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"Enfortumab vedotin","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-13","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Phase II Multicenter Study of Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-10-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective response rate (ORR)","timeFrame":"At every restaging (prior to every 2nd or 3rd cycle) until the end of the study therapy and during follow-up until PD"}],"references":[{"citation":"Chandran EBA, Atiq S, Simon N, Girardi D, Ley L, Cordes L, Patel R, Wang TF, Kydd AR, Redd B, Boudjadi S, Stukes I, Banday R, Smith E, Akbulut D, Niglio S, Gurram S, Steinberg S, Apolo AB. E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationale. Future Oncol. 2025 Jun;21(13):1625-1630. doi: 10.1080/14796694.2025.2497719. Epub 2025 May 27.","pmid":"40421891","type":"DERIVED"}],"start_date":{"date":"2026-01-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)","url":"https://clinicaltrials.gov/study/NCT06041503"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/e-virtue-nct06041503"}